XOMA Corporation June 15th Short Interest Update

XOMA Corporation (NASDAQ:XOMA) stated loss of 224,237 shares or 1.7% in the short interest. The short interest registered from 13,254,846 on May 31,2016 to 13,030,609 on June 15,2016. In terms of floated shares, the shorted positions stood at 11.1%. The stock has been averaging 744,481 shares daily in trading and would need 18 days to cover the shorts. The information was released by Financial Industry Regulatory Authority, Inc (FINRA) on June 24th after market close.

XOMA Corporation (NASDAQ:XOMA): The stock opened at $0.53 on Friday but the bulls could not build on the opening and the stock topped out at $0.55 for the day. The stock traded down to $0.50 during the day, due to lack of any buying support eventually closed down at $0.52 with a loss of -7.90% for the day. The stock had closed at $0.57 on the previous day. The total traded volume was 9,253,391 shares.

The company shares have dropped -85.79% from its 1 Year high price. On Jul 13, 2015, the shares registered one year high at $4.93 and the one year low was seen on Jun 24, 2016. The 50-Day Moving Average price is $0.66 and the 200 Day Moving Average price is recorded at $0.88.

XOMA Corporation (NASDAQ:XOMA) has tumbled 10.01% during the past week and has dropped 25.18% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 8.52%. XOMA Corporation (NASDAQ:XOMA) has underperformed the index by 22.92% in the last 4 weeks. Investors should watch out for further signals and trade with caution.

XOMA Corporation is engaged in the discovery and development of antibody-based therapeutics. The Companys lead product candidate, gevokizumab, is a potent, humanized allosteric-modulating monoclonal antibody that binds to the inflammatory cytokine interleukin-1 beta (IL-1 beta). The Company has initiated three pivotal clinical trials evaluating gevokizumab for the treatment of non-infectious intermediate, posterior or pan-uveitis (NIU) and Behcets disease uveitis. The Company also has a gevokizumab Proof-of-Concept (POC) development program to identify other illness for late-stage development. These studies are known as the EYEGUARD program, which includes EYEGUARD-A (patients with active NIU), EYEGUARD-B (patients with Behcets disease uveitis outside of the United States), and EYEGUARD-C (patients with a history of NIU controlled with systemic treatment).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.